News · Latest treatments
Treatment news lands as press releases and jargon. We translate it: what's approved, what's coming, and the questions worth raising with your neurologist — with every source one click away.
Hand-curated · updated July 2026 · every card links to its original source
Tolebrutinib crosses the blood-brain barrier to calm the slow-burn inflammation behind disability progression. In the HERCULES trial it delayed progression by 31% in non-relapsing secondary progressive MS. Approved in Europe; the US FDA has asked for more information, with guidance expected during 2026.
The FDA has extended Ocrevus (ocrelizumab) to paediatric relapsing-remitting MS — a meaningful moment for families, where treatment options have long lagged behind those for adults.
The newer subcutaneous form of ocrelizumab — a ten-minute injection instead of an infusion — kept 96.7% of people relapse-free across 96 weeks, making high-efficacy treatment lighter to live with.
The cell therapies that transformed blood cancer are now being tested in MS. KYV-101 has FDA clearance for a phase 2 trial in refractory progressive MS, with several other candidates (IMPT-514, AZD0120) entering early trials. Experimental — and genuinely new territory.
Stepping back: today's landscape spans more than twenty disease-modifying therapies, with growing evidence for starting high-efficacy treatment early. If your current therapy was chosen years ago, it may be worth a fresh conversation.
For rolling updates between our curation passes, MSAA's monthly "What's New in MS Research" is the steadiest, least sensational digest we know. It's where several of this page's stories were first gathered.